A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
We report the results from one site of a two-site, double-blind, placebo-controlled comparison study of gepirone extended release (ER) and imipramine in the management of major depression. In the study, 123 subjects with DSM-III-R major depression were randomized to 8 weeks of treatment with gepirone ER (10-60 mg/day), imipramine (50-300 mg/day), or placebo. According to last observation carried forward (LOCF) analyses of 120 intent-to-treat subjects, both gepirone ER and imipramine were superior to placebo at Weeks 6 and 8 on the Hamilton Rating Scale for Depression 17- and 28-item (HAM-D-17 and HAM-D-28) instruments, the Clinical Global Impressions (CGI) Severity of illness scale, and the total Bech Six-Item Core Depression Cluster score. Gepirone ER was better tolerated than imipramine when judged by dropout rates for adverse events.
Feiger
A D
AD
Feiger Health Research Center, Wheat Ridge, CO 80033, USA.
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000627:therapeutic use*
D000928:Antidepressive Agents; D003692:Delayed-Action Preparations; D011743:Pyrimidines; C039979:gepirone; D007099:Imipramine